Las Vegas Sands......beobachten

leicht schlechtere Arbeitsmarktdaten, die US-Futures haben rot reagiert.  

Ich bleibe bei meinem Fahrplan.
Ok, der Zug hat etwas Verspätung.  

trotz weniger guten Konjunkturdaten.
Hoffentlich bleibt es so bis Feierabend.  

heute zum Wochenende leicht im plus geschlossen.
Ob Rico ' s Fahrplan noch greift ? Der Zug hat dicke
Verspätung, aber auch Verspätungen können egalisiert werden.

Optimistisch bleiben -  vllt. hat St. Nikolaus am Montag ein dickes
Paket für LVS.

Allen ein schönes WE.  

 

 

zu bieten?  

Der Einzelhandel ist zufrieden, die Weihnachtsumsätze brummen,
aber noch scheint die Stimmung an den Börsen unterkühlt.
Ob die Ankündigung von Ben Bernanke, wenn nötig, weitere Staatsanleihen
zu kaufen - also die Druckmaschine wieder anwerfen - für Verstimmung sorgt ?

Noch hoffe ich auf die Jahresendralley.  

Was hast Du denn zu bieten, außer dusseligen postings ?  

Las Vegas Sands Corp. (NYSE: LVS - News) continues to charge higher after reporting an awesome 48% earnings surprise in late October. With a bullish next-year estimate calling for 76% growth, this Zacks #1 rank stock is no crap shoot on momentum.

Las Vegas Sands provided an update on its business on October 29 with Q3 results that handily beat expectations.

Third-Quarter Results

Revenue for the period was up 67% from last year to $1.91 billion. Earnings also came in strong at 34 cents, 48% ahead of the Zacks Consensus Estimate.

Not only did the company's domestic properties and interests perform well, it also saw solid gains in its international assets, with its Marina Bay Sands property in Singapore generating the highest adjusted property EBITDA and EBITDA margin in the company's history.

Its majority interest in Sands China was also strong, with revenue up 28% from last year to $1.08 billion.

Balance Sheet

Operating in a capital intensive business means Las Vegas Sands has had to borrow in order to fuel its growth, with a total debt load of $10.14 billion against $2.39 billion in unrestricted cash.

Estimates

We saw some decent movement in estimates off the good quarter, with the current year adding 24 cents to 97 cents and the next-year estimate gaining 54 cents to $1.67, a bullish 73% growth projection.

Valuation

But in spite of the recent gains, the valuation picture is still in check with a PEG ratio .69, well below the benchmark for value of 1.

12-Month Chart

On the chart, shares have been strong since July, recently hitting a new multi-year high above $51 on the good quarter. The stochastic below the chart is signaling that shares are trading below over-bought territory. Look for support from the long-term trend on any weakness, take a look below.

Last Week's Momentum Zacks Rank Buy Stocks


DSW Inc. (NYSE: DSW - News) just hit a new multi-year high after jumping higher on strong Q3 results that once again beat expectations. With estimates on the rise and a compelling valuation, this Zacks #1 rank stock has a step up on its momentum peers. Read Full Article.

Foot Locker, Inc. (NYSE: FL - News) recently jumped to a new multi-year high after reporting an impressive 94% Q3 earnings surprise in mid November. With an average earnings surprise of 51% over the last three quarters and a bullish growth projection, this Zacks #1 rank stocks scores more than a few points for team momentum. Read Full Article.

Hormel Foods Corp. (NYSE: HRL - News) recently hit a new all-time high after jumping higher on a 14% Q3 earnings surprise. With an average earnings surprise of 13% over the last four quarters and rising estimates, this Zacks #1 rank stock offers a hearty serving of momentum. Read Full Article.

Deckers Outdoor Corp. (NasdaqGS: DECK - News) recently surged to a new all-time high ahead of the holidays after reporting strong Q3 results in late October that included a 15% earnings surprise. With an average earnings surprise of 54% over the last four quarters and 11% growth projection, this Zacks #1 rank stock has momentum to boot. Read Full Article.

http://finance.yahoo.com/news/...S-zacks-2303707473.html?x=0&.v=1  

Balance Sheet

Operating in a capital intensive business means Las Vegas Sands has had to borrow in order to fuel its growth, with a total debt load of $10.14 billion against $2.39 billion in unrestricted cash.  

http://farm6.static.flickr.com/5007/5234581392_3f3353359e_b.jpg  

und LVS-Aktien kaufen, oder per Handy.  

Nikolausbescherung.

Gute Nacht.  

Warnzeichen für Las Vegas Sands :

http://www.fool.com/investing/general/2010/12/06/...-vegas-sands.aspx

Ist dies doch ein möglicher Grund für den leichten Abwärtstrend der letzten Tage ?  

 

fool.com nicht doch recht?  

Positive Nachrichten in Phase II für Brustkrebs Impfstoff

Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data

WORCESTER, Mass., Dec. 6, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (http://www.generex.com/) (BULLETIN BOARD: GNBT) today announced two presentations of data obtained from its on-going Phase II trial of its novel immunotherapeutic AE37 vaccine in breast cancer patients. The presentations, entitled Combination Immunotherapy: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-derived Peptide Vaccine Sequentially or Concurrently with Trastuzumab and Increased prevalence of HLA-DR3 among breast cancer patients: implications for adjuvant HER2/neu peptide vaccine trials, will be made at the 33rd Annual San Antonio Breast Cancer Symposium (http://www.sabcs.org/) in San Antonio, Texas from December 8-12, 2010.

The presentation on combination immunotherapy reports that patients receiving both AE37 and Trastuzumab (Herceptin®), a monoclonal antibody targeting the same protein, have increased specific immune-stimulation of T cells when AE37 is given simultaneous to administration of Trastuzumab rather than following Trastuzumab treatment. These results confirm prior published reports suggesting that the combination of Trastuzumab with active immunotherapy can work synergistically in cancer patients.

The second presentation reports that patients who are genetically predisposed to less efficiently recognize peptides derived from the HER2 protein have an immunological response to the AE37 HER2 peptide vaccine that is similar in robustness to the response in patients not having this predisposition. This is promising confirmation that AE37, which is designed as a self-potentiating peptide vaccine, indeed has improved activity that may be clinically relevant.

The 2010 CTRC-AACR San Antonio Breast Cancer Symposium, an international scientific symposium for interaction and exchange among scientists and clinicians in breast cancer, is presented by Cancer Therapy&Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer. By combining their respective strengths, the San Antonio Breast Cancer Symposium encompasses the full spectrum of breast cancer research and facilitates the rapid transition of new knowledge into improved care for breast cancer patients.

http://www.finanznachrichten.de/...breast-cancer-vaccine-data-008.htm

Gruß

Dude44

 

leider zeigen sie noch keine Wirkung auf den Kurs der BRCX-Aktie.